Nasdaq

Quest Diagnostics Reaches Analyst Target Price

In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
Nasdaq

Quest Diagnostics price target raised to $182 from $179 at BofA

BofA raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $179 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...
Seeking Alpha

Quest Diagnostics targets $10.7B-$10.85B 2025 revenue with focus on advanced diagnostics and acquisitions

CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...
Seeking Alpha

Lucid Diagnostics targets revenue growth with expanded sales initiatives and Medicare coverage prospects

CEO Lishan Aklog highlighted a strong close to 2024 and an optimistic start to 2025, driven by advancements in EsoGuard sales channels, reimbursement milestones, and increased clinical evidence. He ...
moneycontrol.com

Reduce Vijaya Diagnostic Centre: target of Rs 950: ICICI Securities

Vijaya Diagnostic’s (Vijaya) Q2FY26 performance was weaker than our expectations due to a slowdown in core markets of Hyderabad (+3% YoY). Pathology revenue grew at a modest pace of 5.1% YoY on a high ...